Royalty Pharma's Q4 results show portfolio receipts of $742 million and operating cash flow of $678 million. Read why RPRX ...

Tweedy Browne’s 13F portfolio value decreased from $2.10B to $1.48B. Click here to read more about the trades and holdings of ...

Lavos, the alchemist, has been mixed together in a new recipe, given that sweet gold trim, and unleashed in Prime form in ...

MPS offers to cover part of SROs' salaries, training costs ahead of Feb. 17 deadline ...